Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Jasper Therapeutics, Inc. (JSPR) had Return on Tangible Equity of -1826.09% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-75.80M |
|
-- |
|
-- |
|
$83.88M |
|
$-83.88M |
|
$8.08M |
|
$-75.80M |
|
$-75.80M |
|
$-75.80M |
|
$-75.80M |
|
$-75.80M |
|
$-75.80M |
|
$-83.88M |
|
$-82.83M |
|
19.17M |
|
19.17M |
|
$-3.95 |
|
$-3.95 |
|
| Balance Sheet Financials | |
$34.65M |
|
$0.10M |
|
$1.13M |
|
$35.78M |
|
$13.20M |
|
-- |
|
$18.43M |
|
$31.63M |
|
$4.15M |
|
$4.15M |
|
$4.15M |
|
28.00M |
|
| Cash Flow Statement Financials | |
$-77.16M |
|
$0.01M |
|
$34.21M |
|
$72.05M |
|
$29.11M |
|
$-42.95M |
|
$6.71M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.62 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-77.16M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-1826.10% |
|
|
Return on Tangible Equity |
-1826.09% |
-211.86% |
|
-1826.09% |
|
$0.15 |
|
$-4.03 |
|
$-4.03 |
|